![Jun Qi: Our article on EP300/CBP bromodomain inhibition in Group 3 medulloblastoma is now published](https://oncodaily.com/pub/uploads/2024/04/IMG_1884-1.jpeg)
Photo taken from Jun Qi/LinkedIn
May 1, 2024, 01:17
Jun Qi: Our article on EP300/CBP bromodomain inhibition in Group 3 medulloblastoma is now published
Jun Qi, Assistant Professor of Medicine at Dana-Farber Cancer Institute, shared a post on LinkedIn:
“It is so exciting to see our collaborative work with Adam Durbin, Ernst Schonbrunn, Martine Roussel, and Brian Abraham to study EP300/CBP bromodomain inhibition in Group 3 medulloblastoma is now published in Nature Communications! It is interesting to see that different type of cancers might rely on EP300/CBP functions very differently. We can use the chemical tool compounds to dissect them out. We are eager to learn more about the pediatric brain tumor and hopefully can find novel therapy for these tough cancers using our chemistry expertise.”
Additional information
Source: Jun Qi/LinkedIn
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Sep 10, 2024, 18:47
Sep 10, 2024, 17:17